STOCK TITAN
  1. Home
  2. Sec-filings
  3. TGNT
  4. [8-K] Totaligent, Inc. Reports Material Event

Totaligent (TGNT) pushes GloMed joint venture and acquisition deadline to April 22, 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Totaligent, Inc. entered into an Extension Amendment to its Binding Letter of Intent with GloMed Solutions Limited Liability Company dated February 22, 2026. The original letter outlines plans for a joint venture and a call option for Totaligent to acquire GloMed, including its operations, intellectual property, and related assets.

The Amendment moves the target dates for negotiating and signing definitive agreements, and for closing the proposed transaction, to April 22, 2026 to allow more time for negotiations and due diligence. The binding exclusivity period is also extended through April 22, 2026, with all other terms of the letter of intent remaining in effect.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →

 

 

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 22, 2026

 

TOTALIGENT, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-41803

 

80-0142655

(State or other

jurisdiction of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3651 FAU Boulevard, Suite 400

Boca Raton, Florida

 

33431

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (561) 360-3565

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12b of the Act:

 

Title of Each Class

Trading Symbol(s)

Name of Each Exchange Registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On March 22, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 22, 2026 (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”). As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 23, 2026, the LOI sets forth the principal terms for a proposed transaction pursuant to which the Company and GloMed would form a joint venture and the Company would receive a call option to acquire GloMed, including its business operations, intellectual property, and related assets.

 

The Amendment extends the target date for the negotiation and execution of definitive agreements (including, but not limited to, joint venture agreements, asset contribution agreements, intellectual property assignment agreements, and related transaction documents), and the target closing date of the transaction, to April 22, 2026, to allow additional time for completion of negotiations and due diligence. The binding exclusivity period set forth in the LOI has been extended through April 22, 2026, or such earlier date as provided in the LOI, and is not affected by the Amendment. Except as expressly amended, all terms and conditions of the LOI remain in full force and effect.

 

The foregoing description is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

10.1

 

Extension Amendment to Binding Letter of Intent, dated March 22, 2026, between Totaligent, Inc. and GloMed Solutions Limited Liability Company.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

TOTALIGENT, INC.

 

 

 

 

 

Date: March 26, 2026

By:

/s/ EDWARD C DEFEUDIS   

 

 

 

Edward C. DeFeudis

CEO

 

 

 

 

 

 

3

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Totaligent (TGNT) change in its agreement with GloMed?

Totaligent signed an Extension Amendment to its Binding Letter of Intent with GloMed. This pushes back the target dates for negotiating, signing, and closing definitive joint venture and acquisition documents to April 22, 2026, while keeping all other LOI terms in place.

What is the purpose of Totaligent’s proposed transaction with GloMed?

The proposed transaction contemplates forming a joint venture and giving Totaligent a call option to acquire GloMed. That acquisition would include GloMed’s business operations, intellectual property, and related assets, subject to negotiation and execution of definitive agreements described in the letter of intent.

How long is the exclusivity period between Totaligent and GloMed now?

The binding exclusivity period in the letter of intent has been extended through April 22, 2026. It remains subject to earlier termination as provided in the original LOI, but otherwise continues unchanged under the Extension Amendment executed on March 22, 2026.

Did the Extension Amendment change other terms of the GloMed LOI for TGNT?

The Extension Amendment only adjusts timing and related exclusivity; all other LOI terms stay in effect. It does not alter the contemplated joint venture structure, the call option concept, or the types of definitive agreements expected, such as asset contribution and intellectual property assignment agreements.

When is Totaligent now targeting to close the GloMed transaction?

Totaligent and GloMed now target April 22, 2026 for closing the proposed transaction. This new date gives both parties extra time for due diligence and negotiation of definitive joint venture, asset contribution, and intellectual property assignment agreements described in the Binding Letter of Intent.

Filing Exhibits & Attachments

6 documents

Agreements & Contracts

Other Documents